Sign In
Buy LTRN
$2.75
+0.140 (+5.36%)
At Close: Aug 04, 2026
3 Machine Learning Stocks with the Potential to Make You an Overnight Millionaire
06:00am, Wednesday, 01'st May 2024
Keep an eye on machine learning stocks. Companies are tripping over each other for the technology, which involves feeding data to a machine so it can learn and even make human-like decisions.
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and m
Approximately 33% of all non-small cell lung cancer patients in East Asia are never smokers – a growing and unaddressed patient population. Dr. Yashushi Goto a leading lung cancer clinician-scientis
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and m
Lantern Pharma Inc. (LTRN) Q4 2023 Earnings Call Transcript
11:14pm, Monday, 18'th Mar 2024
Lantern Pharma Inc. (LTRN) Q4 2023 Earnings Call Transcript
Lantern Pharma Inc. (LTRN) Q4 2023 Earnings Call Transcript
11:14pm, Monday, 18'th Mar 2024
Lantern Pharma Inc. (LTRN) Q4 2023 Earnings Call Transcript
Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights
04:02pm, Monday, 18'th Mar 2024
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and m
Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284
08:00am, Friday, 15'th Mar 2024
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary AI and machine learni
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating & Financial Results on March 18th, 2024 at 4:30 p.m. ET
07:30am, Monday, 11'th Mar 2024
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and m
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a leader in AI-driven cancer drug discovery and development, announced that it will be presenting at a virtual conference being hosted by H
Lantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor Cancers
08:01am, Thursday, 15'th Feb 2024
DALLAS--(BUSINESS WIRE)--Press release about Lantern Pharma's ADC program focused on cryptophycin drug-payload ADC being developed in collaboration with Bielefeld.
DALLAS--(BUSINESS WIRE)--Starlight Therapeutics— a Lantern Pharma (Nasdaq: LTRN) subsidiary focused exclusively on the clinical development of therapies for central nervous system and brain cancers
The 3 Most Undervalued AI Penny Stocks to Buy in December
08:05am, Wednesday, 13'th Dec 2023
It's easy to understand why investors remain curious about AI penny stocks in December and beyond. Leading companies in the artificial intelligence (AI) industry have multiplied in value in 2023.
FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in High-Grade B-cell Lymphomas (HGBL)
08:00am, Thursday, 30'th Nov 2023
DALLAS--(BUSINESS WIRE)--FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in High-Grade B-cell Lymphomas (HGBL). This is the second ODD for LP-284.
Lantern Pharma Inc. (LTRN) Q3 2023 Earnings Call Transcript
05:28am, Thursday, 09'th Nov 2023
Lantern Pharma Inc. (NASDAQ:LTRN ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Panna Sharma - President and Chief Executive Officer David Margrave - Chief Financi
